CN106714819A - 治疗普拉德‑威利综合征的方法 - Google Patents

治疗普拉德‑威利综合征的方法 Download PDF

Info

Publication number
CN106714819A
CN106714819A CN201580049147.2A CN201580049147A CN106714819A CN 106714819 A CN106714819 A CN 106714819A CN 201580049147 A CN201580049147 A CN 201580049147A CN 106714819 A CN106714819 A CN 106714819A
Authority
CN
China
Prior art keywords
alkyl
substituted
oxytocin receptor
selective oxytocin
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580049147.2A
Other languages
English (en)
Chinese (zh)
Inventor
帕斯卡尔·丹格拉斯
迈克尔·雷迪
保罗·考纳尔
苏达考迪·阿拉加萨米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Priority to CN202110278199.4A priority Critical patent/CN112773765A/zh
Publication of CN106714819A publication Critical patent/CN106714819A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580049147.2A 2014-09-19 2015-09-14 治疗普拉德‑威利综合征的方法 Pending CN106714819A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110278199.4A CN112773765A (zh) 2014-09-19 2015-09-14 治疗普拉德-威利综合征的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052957P 2014-09-19 2014-09-19
US62/052,957 2014-09-19
PCT/US2015/049911 WO2016044131A1 (en) 2014-09-19 2015-09-14 Method of treating prader-willi syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110278199.4A Division CN112773765A (zh) 2014-09-19 2015-09-14 治疗普拉德-威利综合征的方法

Publications (1)

Publication Number Publication Date
CN106714819A true CN106714819A (zh) 2017-05-24

Family

ID=54238564

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580049147.2A Pending CN106714819A (zh) 2014-09-19 2015-09-14 治疗普拉德‑威利综合征的方法
CN202110278199.4A Pending CN112773765A (zh) 2014-09-19 2015-09-14 治疗普拉德-威利综合征的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110278199.4A Pending CN112773765A (zh) 2014-09-19 2015-09-14 治疗普拉德-威利综合征的方法

Country Status (16)

Country Link
US (3) US10441627B2 (enExample)
EP (2) EP3666258B1 (enExample)
JP (3) JP6599447B2 (enExample)
CN (2) CN106714819A (enExample)
CA (1) CA2957224A1 (enExample)
DK (1) DK3666258T3 (enExample)
ES (2) ES2775425T3 (enExample)
FI (1) FI3666258T3 (enExample)
HR (1) HRP20240166T1 (enExample)
HU (1) HUE065829T2 (enExample)
LT (1) LT3666258T (enExample)
PL (1) PL3666258T3 (enExample)
PT (1) PT3666258T (enExample)
RS (1) RS65144B1 (enExample)
SI (1) SI3666258T1 (enExample)
WO (1) WO2016044131A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714819A (zh) * 2014-09-19 2017-05-24 辉凌公司 治疗普拉德‑威利综合征的方法
WO2019032946A1 (en) 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING OXYTOCIN
BR112020001832A2 (pt) 2017-08-11 2020-07-28 Ferring B.V. método de produção de uma composição farmacêuti-ca
US10736894B2 (en) 2018-02-15 2020-08-11 Ovid Therapeutics Inc. Methods of treating developmental syndromes with PDE10A inhibitors
CA3112190A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
CA3112185C (en) 2018-09-20 2025-10-07 Acadia Pharmaceuticals Inc. STABLE INTRANASAL FORMULATIONS OF CARBETOCINE
CA3205469A1 (en) * 2020-12-18 2022-06-23 The General Hospital Corporation Probiotics compositions and method of using the same to enhance growth and social function in children
JP2024511199A (ja) * 2021-03-26 2024-03-12 オーティーフォービー 嚥下障害の治療

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122285A1 (en) * 2008-03-31 2009-10-08 Ferring B.V. Oxitocin analogues
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
WO2011147889A1 (en) * 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
CN102656183A (zh) * 2009-09-21 2012-09-05 辉凌国际制药（瑞士）有限公司 催产素受体激动剂
CN103124554A (zh) * 2010-09-30 2013-05-29 辉凌公司 药物组合物
WO2014095773A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
WO2014111356A1 (en) * 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544662B2 (en) 1993-06-17 2009-06-09 Carle Development Foundation Polypeptides useful for appetite suppression
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2010538991A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのｓｆｌｌｒ−ｏｈおよびムラミルジペプチドの使用
JP2010539028A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのメラニン凝集ホルモンおよびＭｅｔ−エンケファリンの使用
WO2009033820A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033768A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2317845A4 (en) 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
WO2012149472A2 (en) 2011-04-27 2012-11-01 Ignite Institute For Individualized Health Methods, compositions, and kits for treating and preventing neurological conditions
CN106414479B (zh) 2014-06-03 2021-08-03 豪夫迈·罗氏有限公司 作为催产素激动剂的肽
CR20160562A (es) 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
PL3177635T3 (pl) 2014-08-07 2019-02-28 F. Hoffmann-La Roche Ag Sposoby wytwarzania analogów oksytocyny
CN106714819A (zh) 2014-09-19 2017-05-24 辉凌公司 治疗普拉德‑威利综合征的方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
WO2009122285A1 (en) * 2008-03-31 2009-10-08 Ferring B.V. Oxitocin analogues
CN102656183A (zh) * 2009-09-21 2012-09-05 辉凌国际制药（瑞士）有限公司 催产素受体激动剂
WO2011147889A1 (en) * 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
CN103124554A (zh) * 2010-09-30 2013-05-29 辉凌公司 药物组合物
WO2014095773A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
WO2014111356A1 (en) * 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRÉSMARTINAMATTHEWSTATEAGEORGE MANDERSONAWALTER MKAYEBJEANNE M: "Cerebrospinal Fluid Levels of Oxytocin in Prader–Willi", 《SOCIETY OF BIOLOGICAL PSYCHIATRY》 *

Also Published As

Publication number Publication date
JP2020019790A (ja) 2020-02-06
JP2021098745A (ja) 2021-07-01
EP3666258B1 (en) 2023-11-15
US20240082344A1 (en) 2024-03-14
HUE065829T2 (hu) 2024-06-28
PL3666258T3 (pl) 2024-04-08
EP3666258A1 (en) 2020-06-17
FI3666258T3 (fi) 2024-02-09
PT3666258T (pt) 2024-02-01
HRP20240166T1 (hr) 2024-04-26
US20200129584A1 (en) 2020-04-30
EP3193907B1 (en) 2020-01-01
JP2017532316A (ja) 2017-11-02
WO2016044131A1 (en) 2016-03-24
CN112773765A (zh) 2021-05-11
DK3666258T3 (da) 2024-02-05
JP6599447B2 (ja) 2019-10-30
ES2970059T3 (es) 2024-05-24
RS65144B1 (sr) 2024-02-29
EP3193907A1 (en) 2017-07-26
JP6921154B2 (ja) 2021-08-18
LT3666258T (lt) 2024-01-10
SI3666258T1 (sl) 2024-04-30
US20170326200A1 (en) 2017-11-16
US10441627B2 (en) 2019-10-15
CA2957224A1 (en) 2016-03-24
ES2775425T3 (es) 2020-07-27

Similar Documents

Publication Publication Date Title
JP6921154B2 (ja) プラダー・ウィリー症候群を治療する方法
US10092564B2 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP2754440B1 (en) Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis
CN119072304A (zh) 用于治疗cns相关障碍的神经活性类固醇
CA2899602A1 (en) Pharmaceutical uses of inorganic nitrites
Elbaridi et al. Current concepts of phenylpiperidine derivatives use in the treatment of acute and chronic pain
MX2014002125A (es) Tratamiento de sintomas asociados a gastroparesia femenina.
WO2025255116A1 (en) Methods of treatment for opioid-induced ventilatory depression and muscle rigidity
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
PH12015500915B1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
US20100215635A1 (en) Small molecules to induce weight loss or to reduce weight gain
US20150335677A1 (en) Argon is a mu opioid receptor antagonist
Paul Comparison of Tramadol and Pethidine for Control of Shivering in Regional Anaesthesia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination